AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02657499 — intervention group
Intervention type: OTHER
Intervention: Medicaid Expansion
Description: There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
Study NCT03555253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience-Based Program for Support Partners of PwMS
Description: Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners. The MyHealios Resilience Program for PwMS and their Support Partners has been designed to be interactive and include skills-based activities led by the Resilience coach. This includes skills of communication, problem solving, and learning about resilience and cognition in MS.
Study NCT03234920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)
Description: 1.5 g of HMB dissolved in 200 ml of fruit juice will be provided for 12 weeks twice daily
Study NCT03234920 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be 200 ml of fruit juice given twice daily
Study NCT03250338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib
Description: Crenolanib will be administered orally
Study NCT03250338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: HAM regimen~FLAG-Ida
Study NCT03250338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: HAM regimen~FLAG-Ida
Study NCT03250338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: HAM regimen
Study NCT03250338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitoxantrone
Description: HAM regimen
Study NCT03250338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally
Study NCT03250338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: FLAG-Ida regimen
Study NCT03250338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fludarabine
Description: FLAG-Ida regimen
Study NCT03250338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: FLAG-Ida regimen
Study NCT01746589 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: bilateral myopic LASIK
Description: 200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
Study NCT01528319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MG-1
Description: Being embedded in the area of glenohumeral instability by arthroscopic Bankart repair method.
Study NCT04490577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Pilates exercises are a combined exercise procedure including strengthening and stretching. Pilates exercises are performed with different equipment for example; therabands, mats, reformer, etc.
Study NCT04490577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Whole-body vibration gives vibration to the body with a platform at different frequencies (Power-plate). The participant performed exercises on the platform.
Study NCT03364777 — intervention group
Intervention type: OTHER
Intervention: emotional state
Description: anxiety or depression state evaluated by emotional scale
Study NCT01112436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: periarticular injection of multidrug regimen
Description: periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg
Study NCT01112436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: none of medication preoperatively and intraoperatively
Description: Patients in Group C wil receive none of medication preoperatively and intraoperatively
Study NCT04944667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TAVR planning
Description: TAVR planning without VR vs after VR
Study NCT00485953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: risedronate 35 mg per week
Study NCT05411172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastery Learning Model for Chemical, Biological, Radiological, and Nuclear threats and hazards (MLM-CBRN Education Program) on student nurses
Description: The MLM-CBRN Education Program was carried out with the students in the experimental group face-to-face as theoretical and practical education once a week for four weeks. . The data were collected before and right after the intervention and in the 1st and 3rd months after the intervention using the Personal Information Form, Nursing Student CBRN Knowledge Test, Nursing Student CBRN Attitude Scale, and Nursing Student CBRN Self-Efficacy Scale. Moreover, only the knowledge scores of the students in the experimental group were collected using the unit follow-up tests, which enabled us to check whether the Learning Objective related to the unit taught was achieved. During the skill training, the START Triage and JumpSTART Triage Skill Check List, Gas Mask Wearing-Removing Skill Check List, and Level C Clothes Wearing-Removing Skill Check List were scored for each student in the experimental group after observing the students twice.
Study NCT02129868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop (Android Closed-Loop platform)
Description: The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.~The Android Closed-Loop platform employs the Medtronic MiniMed Paradigm® Veo™ insulin pump system with CGM capability (use of MiniLink™Transmitter and sensor). A Radiofrequency (RF) translator module translates the RF protocol to Bluetooth® technology. An Android device containing an algorithm will use sensor glucose data to calculate pump strokes.
Study NCT02129868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop (Android Closed-Loop platform)
Description: The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.~The Android Closed-Loop platform employs the Medtronic MiniMed Paradigm® Veo™ insulin pump system with CGM capability (use of MiniLink™Transmitter and sensor). A Radiofrequency (RF) translator module translates the RF protocol to Bluetooth® technology. An Android device containing an algorithm will use sensor glucose data to calculate pump strokes.
Study NCT01216072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5 mg/day oral capsule
Study NCT01216072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard MS DMTs
Study NCT03359564 — intervention group
Intervention type: PROCEDURE
Intervention: micro endoscopic discectomy
Description: the patients receive micro endoscopic discectomy surgery therapy
Study NCT00489801 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Exercise intervention and lifestyle counseling at centre or exercise intervention at home
Study NCT00532168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir + emtricitabine + efavirenz
Description: tenofovir + emtricitabine + efavirenz, approved dose, oral route, QD
Study NCT00532168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir + emtricitabine + lopinavir-ritonavir
Description: tenofovir + emtricitabine (QD) + lopinavir-ritonavir (BID), oral route, approved dose
Study NCT00532168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir + emtricitabine + atazanavir-ritonavir
Description: tenofovir + emtricitabine + atazanavir + ritonavir (100 mg), oral route, approved dose, QD
Study NCT03656276 — intervention group
Intervention type: BEHAVIORAL
Intervention: Tool to improve Participation In Clinical Trials (ToPIC)
Description: The Tool to improve Participation In Clinical Trials (ToPIC) is a communication tool to facilitate clinical trial decision making conversations between oncologists and patients.
Study NCT00756457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bracing
Description: Participants will wear a brace that includes ankle stirrup support and medial longitudinal arch support. The brace will be worn during weight-bearing tasks throughout the 12-week study.
Study NCT00756457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bracing
Description: Participants will wear a brace that includes ankle stirrup support and medial longitudinal arch support. The brace will be worn during weight-bearing tasks throughout the 12-week study.
Study NCT00756457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: Participants performed strengthening exercises progressively longer each time for up to 3 sets of 30 repetitions twice daily by the third visit. Exercises included bilateral heel raises, foot adduction/rear foot inversion with thera-tubing, and unilateral heel raises. Participants increased resistance by using thera-bands with higher levels of resistance over the 12 week period. The amount of resistance was progressed according to patient tolerance at each visit. Strengthening exercises were preceded by the control stretching exercises which constituted a warm up.
Study NCT00756457 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: Subjects were provided with written descriptions and pictures demonstrating 2 range-of-motion exercises which included a wall calf stretch, and a supine ankle active range-of-motion exercise. Subjects were instructed to perform 3 sets of the stretching exercises, 2 times a day, similar to the intervention group. Each stretching exercise was performed twice and held for 30 seconds.
Study NCT00756457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Subjects were provided with written descriptions and pictures demonstrating 2 range-of-motion exercises which included a wall calf stretch, and a supine ankle active range-of-motion exercise. Subjects were instructed to perform 3 sets of the stretching exercises, 2 times a day, similar to the intervention group. Each stretching exercise was performed twice and held for 30 seconds.
Study NCT01627951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NF54
Description: Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
Study NCT01627951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF135
Description: Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
Study NCT01627951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NF166
Description: Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
Study NCT03809598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: See Mindfulness Based Cognitive Therapy (MBCT) Arm description
Study NCT01612273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triflusal
Description: Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
Study NCT01612273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
Study NCT04129047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnichroma (one shade universal) composite by Tokuyama
Description: Omnichroma is a single shade composite that is intended to have a color blending potential. It eliminates the shade matching procedures and makes it easier to avoid individual errors in shade matching in composite restorations.
Study NCT04129047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA
Description: a multiple shade universal composite that needs prior shade selection procedure
Study NCT01240915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: once every 7 days for 1- 3 doses
Study NCT01240915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiStem low dose
Description: 1-3 doses
Study NCT01240915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose at week 8
Study NCT01240915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiStem low dose
Description: Single dose at week 8
Study NCT01240915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose Day 1
Study NCT01240915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiStem high dose
Description: Single dose Day 1
Study NCT01240915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiStem high dose
Description: Single dose at week 8
Study NCT03423329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brufen
Description: Brufen Syrup
Study NCT03423329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brufen
Description: Brufen Syrup
Study NCT03423329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cital
Description: Cital Cyrup
Study NCT03423329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cital
Description: Cital Cyrup
Study NCT03423329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Brufen
Description: Sansovit Syrup
Study NCT03423329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Brufen
Description: Sansovit Syrup
Study NCT04060693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.5
Description: Investigational Medical Device collecting spectral raman data from tissue.
Study NCT04706689 — intervention group
Intervention type: BEHAVIORAL
Intervention: SWADOC tool
Description: The tool explores some oral and pharyngeal components of swallowing as well as a range of prerequisite and related components of swallowing in DOC patients.~It is composed of an average of 50 qualitative items and a subsection named SWADOC-scored comprising 8 quantitative items.
Study NCT04706689 — intervention group
Intervention type: BEHAVIORAL
Intervention: FOTT-SAS
Description: Facial Oral Tract Therapy Swallowing Assessment of Saliva : the results of the SWADOC-scored in one of the sessions will be compared to the FOTT Swallowing Assessment of Saliva (FOTT-SAS) (27). The test is based on 7 questions under which if items 1-4 are answered Yes and items 5-7 are answered No, oral intake should be initiated. The FOTT-SAS includes items that can be scored based on the administration of the SWADOC tool. In that respect, no additional administration will be required
Study NCT03836859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 20μg/mL
Description: Study Eye (For subjects randomized to rhNGF group) Day 1: One drop instilled into study eye (35 μL, corresponding to 0.70 μg of rhNGF).~Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into study eye (210 μL, corresponding to 4.20 μg of rhNGF).~Total dose in the study eye will be 31 drops (1085 μL, equivalent to 21.7 μg rhNGF) over 6 days.
Study NCT03836859 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle: formulation containing L-methionine as excipient.
Study NCT00905905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
Study NCT00905905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe-Simvastatin
Description: Ezetimibe-Simvastatin 10-40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
Study NCT02474043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hep-Net Intervention
Description: The Hep-Net Intervention is a web-based questionnaire and tailored feedback system designed to increase readiness to change with respect to several behaviors. The behaviors include (1) reducing or quitting drug use; (2) using sterile equipment every time one injects drugs; (3) undergoing screening for hepatitis C; (4) receiving training to use naloxone to prevent death due to opioid overdose.
Study NCT02474043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Clients receive health education and risk reduction counseling from a trained prevention specialist.
Study NCT02474043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Clients receive health education and risk reduction counseling from a trained prevention specialist.
Study NCT03815864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
Description: Anti-AT1R antibodies were tested on pre-transplantation sera using ELISA kit (Lot #30, One Lambda, Canoga Park, CA)
Study NCT01972932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bio K+® 2 capsules orally (or via nasogastric tube)
Description: Bio-K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
Study NCT01972932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
Study NCT03735953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Retroflexion in the total colon
Description: retroflexion in the cecum or proximal ascending colon and slow withdrawal to the rectum
Study NCT03080493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 600mg
Description: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
Study NCT03080493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Packaged identical to gabapentin dosing
Study NCT03080493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen/codeine and ibuprofen
Description: Over the counter analgesic medications
Study NCT03080493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen/codeine and ibuprofen
Description: Over the counter analgesic medications
Study NCT02358447 — intervention group
Intervention type: PROCEDURE
Intervention: TKR
Description: non-navigated versus computer-navigated total knee replacement
Study NCT02306590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calogen
Study NCT03250338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Idarubicin
Description: FLAG-Ida regimen
Study NCT03250338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: FLAG-Ida regimen
Study NCT03250338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: G-CSF
Description: FLAG-Ida regimen
Study NCT03448172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PF-05221304
Description: a single oral dose of \[14C\]PF-05221304 (50 mg/100 µCi liquid formulation)
Study NCT03668340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked
Study NCT03387657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study NCT03387657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study NCT02751619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Description: Lidocaine patch 5% was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
Study NCT02751619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch
Description: A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
Study NCT02822833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node mapping
Description: Before laparoscopic hysterectomy and lymphadenectomy procedure for endometrial cancer, Indocyanine green solution will be injected through cervix. Then the surgeon will look for sentinel lymph nodes under fluorescence visualization.
Study NCT00892814 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial breast irradiation
Description: 40 Gy/15 fractions, 3 weeks
Study NCT00892814 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole breast irradiation
Description: 40 Gy/15 fractions, 3 weeks
Study NCT02661061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.